Immune System
|
Senescence as cell-autonomous mechanism in inclusion body myositis – new therapies for old cells
Funding line:
First and Second Applications

Workroup Myositis with Vera Dobelmann (left), Christopher Nelke (center) and Derya Cengiz (right).
(© Universitätsklinikum Düsseldorf, Christopher Nelke)
Inclusion body myositis (IBM) is a muscle disease characterized by chronic inflammation. Current treatment approaches have not been effective in halting the progression of the disease.
When cells are exposed to prolonged stress or damage, they can enter a state in which they stop dividing but continue to affect their environment. This state is termed cellular senescence. In this project, researchers aim to understand how these senescent muscle cells might amplify the progression of IBM. This knowledge could contribute to new treatment strategies that target cellular senescence as a key factor in IBM.